Azacitidine Plus R-CHOP in High-Risk DLBCL

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses a phase I, open-label, multicenter trial of oral azacitidine (CC-486) plus R-CHOP in patients with high-risk, previously untreated diffuse large B-cell lymphoma, grade 3B follicular lymphoma, or transformed lymphoma.

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses a phase I, open-label, multicenter trial of oral azacitidine (CC-486) plus R-CHOP in patients with high-risk, previously untreated diffuse large B-cell lymphoma, grade 3B follicular lymphoma, or transformed lymphoma.

Overall, 33 patients with DLBCL were enrolled in the dose-escalation phase of the trial. They were treated with 100 mg, 150 mg, 200 mg, or 300 mg of oral azacitidine, with the majority of the patients treated with 200 mg and 300 mg. The patients received 7 days of oral azacitidine prior to the first cycle of R-CHOP and 14 days of oral azacitidine prior to cycles 2 through 6. All patients received granulocyte-colony stimulating factor (G-CSF) on day 2 of each cycle of R-CHOP.